Literature DB >> 10832685

Use of nonpreserved human amniotic membrane for the reconstruction of the ocular surface.

L F Mejía1, C Acosta, J P Santamaría.   

Abstract

PURPOSE: To describe the use of nonpreserved human amniotic membrane (NP-AMT) as an alternative to preserved human amniotic membrane (AMT) for the reconstruction of the ocular surface in several diseases.
METHODS: NP-AMT was used in the treatment of five patients with the following diseases: noninvasive conjunctival squamous cell carcinoma, corneal persistent epithelial defect, severe alkali burn, near total limbal deficiency secondary to multiple surgeries, and ocular cicatricial pemphigoid. In some cases, a limbal autograft or allograft was employed simultaneously, sutured on top of the NP-AMT. All sutures were made with 10-0 Nylon and were removed at two weeks.
RESULTS: Ocular surface was satisfactorily reconstructed, eyes were quiet, and patients were comfortable despite prolonged deepithelialization in some cases. There was a case of a limbal autograft ischemia--in the burned patient--that caused partial corneal conjunctivalization. Initially, the NP-AMT looks thickened but thins around the fifth day and looks similar to AMT.
CONCLUSION: Results using NP-AMT are similar to those of AMT. It is a good alternative and it is easily obtained in places were AMT is not available or is too expensive to procure.

Entities:  

Mesh:

Year:  2000        PMID: 10832685     DOI: 10.1097/00003226-200005000-00006

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  2 in total

Review 1.  Current concepts of ocular adnexal surgery.

Authors:  Maria Borrelli; Gerd Geerling
Journal:  GMS Interdiscip Plast Reconstr Surg DGPW       Date:  2013-02-27

2.  Preserved Corneal Lamellar Grafting Reduces Inflammation and Promotes Wound Healing in a Scleral Defect Rabbit Model.

Authors:  Kyoung Woo Kim; Jin Suk Ryu; Jun Yeob Kim; Mee Kum Kim
Journal:  Transl Vis Sci Technol       Date:  2020-06-29       Impact factor: 3.283

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.